Miraluma Test

• The Miraluma Test is a nuclear medicine scan primarily used for cardiac imaging and detecting specific cellular activities.
• It involves injecting a radioactive tracer, technetium-99m sestamibi, which is absorbed by heart muscle cells and certain tumor cells.
• The scan helps diagnose coronary artery disease by showing blood flow to the heart and can identify areas of ischemia or infarction.
• The procedure typically involves two phases (rest and stress for cardiac scans) and uses a SPECT camera to capture images.
• Interpretation of results requires a nuclear medicine physician to assess tracer uptake patterns, indicating normal function, reduced blood flow, or abnormal cellular activity.

What is Miraluma Test and Its Applications?

The Miraluma Test refers to a nuclear medicine imaging procedure that utilizes a radioactive tracer, technetium-99m sestamibi (also known as Tc-99m sestamibi or Cardiolite), to create images of the heart and, in some cases, other tissues. This tracer is absorbed by living cells, making it valuable for assessing cellular function rather than just anatomical structure. Its primary application is in cardiology, where it is instrumental in diagnosing and evaluating coronary artery disease.

A Miraluma scan for heart disease helps physicians assess blood flow to the heart muscle (myocardium) and identify areas that may be deprived of oxygen and nutrients due to narrowed or blocked coronary arteries. By comparing images taken at rest and after stress (either exercise-induced or pharmacologically induced), doctors can differentiate between areas of reversible ischemia (reduced blood flow that improves with rest) and irreversible infarction (heart muscle damage). Beyond cardiac applications, the Miraluma Test can also be used in some instances to detect certain types of tumors, as some cancer cells exhibit increased uptake of the tracer, making them visible on the scan.

How is a Miraluma Scan Performed?

Performing a Miraluma scan involves several steps, ensuring comprehensive evaluation, especially for cardiac assessments. Patients are typically advised to fast for a few hours before the test and avoid caffeine. The procedure generally includes two main phases for cardiac evaluation: a rest study and a stress study.

During the rest phase, a small amount of the radioactive tracer is injected into a vein, usually in the arm. The patient then rests for a period, allowing the tracer to distribute throughout the heart muscle. After this, images are acquired using a special camera called a Single-Photon Emission Computed Tomography (SPECT) scanner. This camera rotates around the patient’s chest, capturing detailed 3D images of the heart.

The stress phase follows, which can be induced either through physical exercise on a treadmill or stationary bicycle, or pharmacologically using medications that mimic the effects of exercise on the heart. At the peak of stress, a second dose of the tracer is injected. After another waiting period, a second set of images is taken with the SPECT camera. The entire procedure, including preparation and imaging, can take several hours.

• Preparation: Fasting, avoiding caffeine, and discussing medications with the doctor.
• Tracer Injection: A small dose of technetium-99m sestamibi is injected intravenously.
• Rest Imaging: Images are taken after the tracer distributes in the heart at rest.
• Stress Induction: Exercise or medication is used to increase heart rate and blood flow.
• Stress Imaging: A second tracer injection and imaging session occur at peak stress.

Interpreting Miraluma Test Results

The Miraluma test results interpretation is performed by a nuclear medicine physician or a cardiologist trained in nuclear imaging. The physician analyzes the images from both the rest and stress phases, looking for patterns of tracer uptake in the heart muscle. Areas with normal blood flow will show uniform uptake of the tracer, appearing bright on the images.

Abnormalities are identified by areas where tracer uptake is reduced or absent. If an area shows reduced uptake during stress but normal uptake at rest, it indicates reversible ischemia, suggesting a blockage that limits blood flow only when the heart is working harder. If an area shows reduced or absent uptake during both stress and rest, it typically indicates a myocardial infarction (heart attack) or scar tissue, meaning that part of the heart muscle is permanently damaged. For non-cardiac applications, increased tracer uptake in specific areas may indicate the presence of certain types of tumors or other abnormal cellular activity. The interpretation of these results is crucial for guiding further diagnostic tests or treatment plans and is always considered in conjunction with the patient’s clinical history and other diagnostic findings.